Intervention Review

You have free access to this content

Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection

  1. Yun Xia1,2,
  2. Hui Luo1,
  3. Jian Ping Liu1,2,*,
  4. Christian Gluud2

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 30 APR 2013

Assessed as up-to-date: 5 DEC 2012

DOI: 10.1002/14651858.CD009004.pub2


How to Cite

Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD009004. DOI: 10.1002/14651858.CD009004.pub2.

Author Information

  1. 1

    Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing, China

  2. 2

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark

*Jian Ping Liu, Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. jianping_l@hotmail.com. jianping@fagmed.uit.no.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Ge 2005 {published data only}
  • Ge X, Song WL, Heng SX, Yang WD. Therapeutic effect observation of phyllanthus tablet for patients with lamivudine resistant hepatitis B. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2005;15(1):50-2.
Huang 2004 {published data only}
  • Huang ZC, Zhu BX, Zheng QJ, Yang SL, Tan B, He JY, et al. A comparative study on phyllanthus compound and lamivudine in the treatment of chronic hepatitis B. Journal of Guangzhou University of Traditional Chinese Medicine 2004;21(3):161--3.
Li 1998 {published data only}
  • Li CQ, Wang XH, Li GQ, Fang HX. Clinical observation of compound phyllanthus for patients with chronic hepatitis B. Journal of New Chinese Medicine 1998;30(6):45-6.
Ouyang 1999 {published data only}
  • Ouyang L. Thymosin and phyllanthus tablets for chronic hepatitis B in 42 cases. Chinese Journal of Traditional and Western Medicine on Liver Disease 1999;9(5):44.
Zhu 2005 {published data only}
  • Zhu YC. Therapeutic effect observation of compound phyllanthus and thymosin alpha 1 for chronic hepatitis B. Anti Infection Pharmacy 2005;2(4):165-6.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Cai 2006 {published data only}
  • Cai XM. Phyllanthus tablets and lamivudine for chronic hepatitis B in 32 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Disease 2006;16(6):368-9.
Chan 2003 {published data only}
Cheng 2005 {published data only}
  • Cheng SL, Yin SS, Liu CY, Zhang JY. Compound phyllanthus tablet and Interferon for children with chronic hepatitis B in 30 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Disease 2005;15(1):59.
Cui 1998 {published data only}
  • Cui YJ, Gao WJ, Qiao HC. Phyllanthusnirud Linn for patients with chronic hepatitis B virus infection. Chinese Journal of Traditional Chinese Medicine and Pharmacy 1998;13(5):74.
Gu 2005 {published data only}
  • Gu HH, Chen QW, Zhou X, Wu WY, Zhao GG. Phyllanthus and vidarabine for chronic hepatitis B in 34 cases. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 2005;13(5):332-3.
He 2008 {published data only}
  • He LF. Therapeutic effect observation of adefovir dipivoxil and phyllanthus for chronic hepatitis B. Sichuan Medical Journal 2008;29(4):435-6.
Huang 1993 {published data only}
  • Huang ZR, Zhong JP, Zhu GL, Chen YD, Wang GQ. Therapeutic effect observation of phyllanthus for patients with chronic hepatitis B. Chinese Journal of Clinical Hepatology 1993;9(2):108-10.
Huang 1999 {published data only}
  • Huang L, Zhang FX, Li CQ. Compound phyllanthus and Interferon for chronic hepatitis B. Shanxi Journal of Traditional Chinese Medicine 1999;20(4):146-7.
Huang 1999a {published data only}
  • Huang KM. Phyllanthus for patients with chronic hepatitis B in 38 cases. Information of Traditional Chinese Medicine 1999;6:32.
Ma 1993 {published data only}
  • Ma FX, Zhang Y. Clinical observation of compound phyllanthus for asymptomatic carriers of hepatitis B. Journal of Shanghai Traditional Chinese Medicine 1993;5:8-9.
Qian 2008 {published data only}
  • Qian HQ. Phyllanthus tablet and adefovir dipivoxil tablet for chronic hepatitis B in 42 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Disease 2008;18(2):115.
Song 2007 {published data only}
  • Song XA, Ma XL, Liu YM. Therapeutic effect observation of phyllanthus capsule for chronic hepatitis B in 98 cases. Shandong Medical Journal 2007;47(23):97-8.
Su 2004 {published data only}
  • Su BL, Xu PR, Lu J. Therapeutic effect observation of phyllanthus tablet and lamivudine for chronic hepatitis B. Hebei Journal of Chinese Medicine 2004;26(2):146-7.
Tian 2004 {published data only}
  • Tian GJ, Feng TB, Tang MZ, Wang XH. Short-term effect of phyllanthus compound and lamivudine in treating chronic hepatitis B: an observation of 30 cases. Journal of Guangzhou University of Traditional Chinese Medicine 2004;21(4):257-9.
Wang 2000 {published data only}
  • Wang SH, Xia SL, Zhang Y, Su Z, Wang LJ, Li DT. Clinical study of phyllanthus for patients with chronic hepatitis B. Journal of Infectious Disease Pharmacy 2000;10(2):31-3.
Wang 2009 {published data only}
  • Wang WX, Zhou WH, Shen LJ. Phyllanthus and adefovir dipivoxil tablets for chronic hepatitis B in 20 cases. Herald of Medicine 2009;28(1):74-5.
Yan 2008 {published data only}
  • Yan J, Liu XQ, Du M, Chen LY. Therapeutic effect observation interferon alpha and phyllanthus capsule for chronic hepatitis B. Journal of Clinical Hepatology 2008;11(1):37-8.
Zhang 2006 {published data only}
  • Zhang MJ, Dong P, Yong J, Teng J, Li ZX. Therapeutic effect observation of phyllanthus for patients with chronic hepatitis B. Journal of Ningxia Medical College 2006;28(5):451-2.
Zhang 2009 {published data only}
  • Zhang HF, Zhu SX, Dong Y, Xu ZQ, Chen DW, Jia WZ, et al. The effect and safety assessment of phyllanthus capsule and adefovir dipivoxil tablet for chronic hepatitis B. Shandong Medical Journal 2009;49(28):60-1.
Zhong 2000 {published data only}
  • Zhong JP, Zhu GL, Huang ZR, Shu ZM, Fei YM, Tang JL, Wang GQ, Chen BC. Therapeutic effect observation of phyllanthus for patients with chronic hepatitis B. Journal of Clinical Hepatology 2000;16(3):186-7.
Zhu 1992 {published data only}
  • Zhu FM, Zhang JQ, Zhang XZ, Zhang XM. Clinical observation of phyllanthus on hepatitis B viral markers. Chinese Journal of Integrated Traditional Chinese and Western Medicine 1992;2(2):10-1.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Aggarwal 2003
  • Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. Journal of Hepatology 2003;38(2):215-22.
Bagalkotkar 2006
Blumberg 1998
  • Blumberg BS. Hepatitis B virus: search for plant-derived antiviral. In: Tomlinson TR, Akerele D editor(s). Medical Plants - Their Role in Health and Biodiversity. Philadelphia: University of Pennsylvania Press, 1998:7.
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
Calixto 1998
Chang 1995
  • Chang CW, Lin MT, Lee SS, Liu KC, Hsu FL, Lin JY. Differential inhibition of reverse transcriptase and cellular DNA polymerase-alpha activities by Lignans isolated from Chinese herbs, phyllanthus Myrtifolius Moon, and tannins from Lonicera Japonica Thunb and Castanopsis hystrix. Antiviral Research 1995;27(4):367-74.
Chang 1997
  • Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine 1997;336(26):1855-9.
Chen 2005
Chinese guideline on chronic hepatitis B 2005
  • Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The Guideline of Prevention and Treatment of Chronic Hepatitis B. Chinese Journal of Hepatology 2005;12:1.
CTU 2011
  • Copenhagen Trial Unit. TSA - Trial Sequential Analysis. http://ctu.dk/tsa/ (accessed 4 September 2012).
DeMets 1987
DerSimonian 1986
EASL 2009
  • European Association for the Study of the Liver. EASL Clinical Practice Guidellines: Management of chronic hepatitis B. Journal of Hepatology 2009; Vol. 50, issue 2:227-42.
Garaci 2007
Gluud 2007
Gluud 2011
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2011, Issue 8. Art. No.: LIVER.
Goldstein 2009
Higgins 2009
  • Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Colloboration, 2009. Available from www.cochrane-handbook.org.
Hu 2009
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Jüni 2001
Kathriarachchi 2005
Khatoon 2006
Kjaergaard 2001
  • Kjaergaard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomised trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
Lam 2006
Lee 1996
Lee 2006
Liaw 2003
Liaw 2005
Liaw 2008
  • Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatology International 2008;2(3):263-83.
Lin 2009
  • Lin L, Lin JW. Advance in research on the thymosin preparation. Chinese Pharmaceutical Affairs 2009;23(7):706-10.
Liu 1997
  • Liu Z, Fu X, Zhang N, Zhang G, Liu D. The inhibitory effect of Chinese herb Phyllanthus on hepatitis B virus in vitro. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1997;11(3):282-5.
Liu 2001
Lok 2009
Lundh 2012
Marcellin 2003
  • Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine 2003;348:808-16.
Mathew 2008
  • Mathew JL, El Dib R, Mathew PJ, Boxall EH, Brok J. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006481.pub2]
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
Mutchnick 1988
Ott 1997
RevMan 2011 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Royle 2003
  • Royle P, Milne R. Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Saconato 2009
  • Saconato H, Atallah ÁN, Souza GM, Parise ER. Thymosin alpha1 for chronic hepatitis B. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD003621]
Savovic 2012a
  • Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savovic 2012b
  • Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Scaglione 2012
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Shi 2004
  • Shi G, Xie YF, Liu XY. Estimation of economic burden of hepatitis B. Chinese Primary Health 2004;8:18-9.
Sun 2010
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 4 Spetember 2012).
Venateswaran 1987
  • Venateswaran PS, Millman I, Blumberg BS. Effects of an extract from phyllanthus niruri on hepatitis B virus and woodchuck hepatitis viruses: in vitro and in vivo studies. Proceedings of the National Academy of Sciences 1987;84(1):274-8.
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
WHO 2001
  • WHO 2001. Introduction of hepatitis B vaccine into childhood immunization services. Management guidelines, including information for health workers and parents. www.who.int/vaccines-documents/DocsPDF01/www613.pdf 2001 (accessed 26 October 2010).
WHO 2008
  • WHO 2008. Hepatitis B. World Health Organization Fact Sheet 204 (Revised August 2008). http://www.who.int/mediacentre/factsheets/fs204/en/index.html 2008 (accessed 26 October 2010).
WHO 2010
  • World Health Organization. Viral hepatitis. Report by the secretariat. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf (accessed January 2010).
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
Xia 2011
  • Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD008960.pub2]